Article
Development and characterization of fused human arginase I for cancer therapy
2023-07-03
Abstract excerpt
Recombinant human arginase I (rhArg I) have emerged as a potential candidate for the treatment of varied pathophysiological conditions ranging from arginine-auxotrophic cancer, inflammatory conditions and microbial infection.. However, rhArg I have a low circulatory half-life, leading to poor pharmacokinetic and pharmacodynamic properties, which necessitating the rapid development of modifications to circumvent th...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 89593043-64fc-5be4-8831-b17d2b0c6f14
- DOI
- 10.21203/rs.3.rs-3118315/v1
